

# urban-gro, Inc.

United States / AgTech Nasdaq Bloomberg: UGRO US ISIN: US91704K2024

Q2/23 report

RATING BUY
PRICE TARGET \$ 6.40
Return Potential 476.6%

High

### **EARNINGS IMPROVED BUT WORK STILL TO BE DONE**

Second quarter reporting featured a solid sequential uptick in sales and earnings. The Q2 AEBITDA loss narrowed to \$-2.0m vs \$-3.4m in the January-to-March period, thanks largely to overhead cost reductions. An uptick in cash and liquid assets to \$8.6m (Q1: \$7.3m) should also cheer investors concerned that the company might have to tap the markets to replenish cash. Management reiterated on the earnings call that UGRO is on a solid financial footing. However, the order backlog was revised downwards from \$105m in Q1 to \$79m after a cannabis project had to be idled when the client ran into financing issues. Despite this setback, we think the company has found a path out of the loss-making woods, and we remain Buy-rated on urban-gro. Updated 2023 FBe and a recalibrated DCF now point to a \$6.4 TP (old: \$7).

Earnings improved but still work to be done urban-gro brass kicked off the earnings call reemphasising their quest to bring adjusted earnings into the black. The AEBITDA loss narrowed to \$-2.0m in Q2 (Q1: \$-3.4m), and the company expects this negative result to be pared down even further in Q3 setting up potential for a positive number in the October-to-December period. UGRO continued to slash overhead expenses in Q2 and sees around \$2.9m in SG&A savings going forward, while several senior staff members also stepped up by offering to accept stock grants in lieu of portions of their salaries for 3 months.

Other Q2 takeaways Operating cash flow totalled \$3.6m in Q2 and was helped by the conversion of a large receivable into cash. The combined working capital effects boosted the cash position to \$8.6m (+18% Q/Q). The business mix was also encouraging in a still tricky environment for the cannabis and produce markets. UGRO began to diversify into other industrial, commercial, and healthcare sectors a year ago, and this is paying off (overleaf). Some two thirds of Q2 sales stemmed from these new sectors. Although the pause in the cannabis project is disappointing, the contract remains open and the company is demonstrating its ability to apply its expertise to other sectors. (p.t.o.)

#### **FINANCIAL HISTORY & PROJECTIONS**

	2020	2021	2022	2023E	2024E	2025E
Revenue (\$m)	25.84	62.11	67.03	90.07	120.95	161.45
Y/Y growth	6.8%	140.4%	7.9%	34.4%	34.3%	32.0%
AEBITDA* (\$m)	-0.65	2.68	-3.90	-5.87	1.38	3.87
AEBITDA margin	-2.5%	4.3%	-5.8%	-6.5%	1.1%	2.4%
Net income (\$m)	-5.07	-0.88	-15.28	-11.91	-3.77	-1.67
EPS (diluted) (\$)	-1.06	-0.09	-1.44	-1.19	-0.38	-0.17
DPS (\$)	0.00	0.00	0.00	0.00	0.00	0.00
FCF (\$m)	-3.81	-9.90	-17.06	-9.28	-1.03	1.70
Net gearing	-83.7%	-71.8%	-23.5%	-10.1%	-6.3%	-12.6%
Liquid assets (\$m)	0.18	34.59	12.01	2.54	1.51	3.21

<sup>\*</sup> adjusted EBITDA

#### RISKS

Risks include but aren't limited to regulatory, financing and market cyclicality, particularly in the cannabis sector.

#### **COMPANY PROFILE**


Risk Rating

urban-gro, Inc is a provider of professional turnkey facility services to the CEA industry and various commercial sectors. Headquartered in Denver, Colorado, the company now operates six offices across North American and one in Europe. Operations are executed by a staff numbering 140 employees.

MARKET DATA	As of 16 Aug 2023
Closing Price	\$ 1.11
Shares outstanding	11.61m
Market Capitalisation	\$ 12.88m
52-week Range	\$ 1.11 / 5.21
Avg. Volume (12 Months)	87,330

Multiples	2022	2023E	2024E
P/E	n.a.	n.a.	n.a.
EV/Sales	0.1	0.1	0.1
EV/AEBITDA	n.a.	n.a.	5.2
Div. Yield	0.0%	0.0%	0.0%

#### STOCK OVERVIEW



COMPANY DATA	As of 30 Jun 2023
Liquid Assets	\$ 8.56m
Current Assets	\$ 34.52m
Intangible Assets	\$ 4.87m
Total Assets	\$ 61.29m
Current Liabilities	\$ 31.82m
Shareholders' Equity	\$ 26.73m

#### **SHAREHOLDERS**

Insiders	28.9%
Institutional Holdings	28.0%
Free Float	43.1%

Table 1: Q2 vs FBe and prior year period

All figures in USDm	Q2/23	Q2/23E	variance	Q2/22	variance	H1/23	H1/22	variance
Revenue	18.8	21.5	-12%	16.3	16%	35.6	37.3	-4%
Gross profit	2.9	3.6	-21%	3.5	-18%	5.7	8.4	-32%
Margin	15.2%	16.9%	-	21.5%	-	16.0%	22.6%	-
AEBITDA	-2.0	-1.2	-	-0.5	-	-5.4	-0.1	-
Margin	-	-	-	-	-	-	-	-

Source: First Berlin Equity Research; urban-gro

**Revenue up 12% Q/Q** The company racked up nearly \$19m in revenues for the quarter (+16% Y/Y). The improvement was led by a welcomed 59% sequential uptick in the higher margin Equipment Systems sales to \$4.6m, while Construction Design-build contributed \$11m to the topline (+8% Q/Q). The 12% miss to our revenue target owes chiefly to a shortfall to our Construction Design-build figure occasioned by the aforementioned cannabis project delay.

**Table 2: Revenue by segment** 

All figures in USDm	Q2/23	Q2/23E	variance	Q2/22	variance	H1/23	H1/22	variance
Equipment systems	4.6	4.0	14%	10.1	-54%	7.5	27.1	-72%
Services	3.0	3.3	-8%	3.0	0%	6.5	6.7	-3%
Construction Design-build	11.0	14.0	-21%	2.9	279%	21.3	2.9	634%
Other	0.2	0.2	0%	0.3	-	0.3	0.6	-50%

Source: First Berlin Equity Research; urban-gro


Meanwhile, commercial clients accounted for some 66% of Q2/23 revenue compared to 20% in the prior year period. The new revenue split underpins management's effort to reduce exposure to the still choppy cannabis and vertical farming markets.

Figure 1: H1/23 revenue breakdown of CEA vs Commercial



Source: First Berlin Equity Research; urban-gro

Figure 2: Order backlog developments



Source: First Berlin Equity Research; urban-gro

Order backlog takes a hit The Q2/23 backlog tallied \$79m (-25% Q/Q) and comprised 32% commercial (non-CEA) projects valued at \$25m. The sequential decline is traced to a cannabis cultivation project that had to be paused when the client encountered funding issues. The project remains open, but management prudently removed the project to maintain high backlog integrity. Construction Design-build accounted for 89% of the backlog at the end of H1, and the company believes several small deals deep in discussion will be inked H2. Management adjusted their 2023 guide accordingly (table 5 overleaf).

**Table 3: Financial highlights** 

5 5			
All figures in USDm	Q2/23	2022	variance
Cash & liquid assets	8.6	12.0	-28%
Financial debt (short- and long-term)	1.9	3.8	-50%
Net debt / (net cash)	-6.7	-8.2	-
Total assets	61.3	62.1	-1%
Shareholders' equity	26.7	34.7	-23%
Equity ratio	44%	56%	-

Source: First Berlin Equity Research; urban-gro

urban-gro exited the six month period with cash and liquid assets of \$8.6m vs \$7.3m at the end of Q1. The 18% Q/Q increase stems from lower working capital consumption with the collection of a large outstanding receivable in Q2. An increase in accounts payable meant UGRO ended the period with negative working capital of roughly \$2.8m.

**Table 4: Cash flow developments** 

All figures in USDm	H1/23	H1/22	variance
Operating cash flow	-0.7	-4.9	-
Cash flow from investing	-0.2	-3.1	-
Free cash flow (FCF)	-0.9	-8.0	-
Cash flow from financing	-2.6	-3.8	-
Net change in cash	-3.4	-11.8	-

Source: First Berlin Equity Research; urban-gro

Table 5: Revised guidance vs our forecasts

	Guidance							
	Unit	Old	New	FBe				
Revenue	\$m	100 - 120	90 - 95	90.1				
Grow th	%	49 - 79	34 - 42	34				
AEBITDA	\$m	-3 to break even	-5 to -6	-5.3				

Source: First Berlin Equity Research; urban-gro

We have adjusted 2023 FBe to account for: (1) the paused cannabis project in the Construction Design-build backlog; (2) the cost cutting measures that will save some \$2.9m in overhead; and (3) the shortfall to our Q2 earnings targets. In terms of sales and earnings cadence in H2/23, we look for the topline to improve sequentially and for AEBITDA to show another incremental improvement in Q3 with a break-even result for this KPI in Q4.

Table 6: Revisions to FBe and target price

	old	new	revision	upside	dividend yield	total return
Price target (\$)	7.0	6.4	-8.6%	476.6%	0.0%	476.6%
		2023E			2024E	
All figures in USD '000	old	new	revision	old	new	revision
Revenue	97,192	90,068	-7.3%	129,588	120,945	-6.7%
Gross profit	15,507	14,315	-7.7%	21,184	20,301	-4.2%
Margin (%)	16.0%	15.9%	-	16.3%	16.8%	-
AEBITDA	-3,014	-5,865	-	265	1,377	419.3%
Margin (%)	-3.1%	-6.5%	-	0.2%	1.1%	-

Source: First Berlin Equity Research estimates

## **VALUATION MODEL**

We remain Buy-rated on urban-gro Although the company is not quite out of the loss-making woods, we think UGRO is on a solid path to reach its profitability targets by YE23 with a business mix less exposed to the volatile cannabis and nascent vertical farming sectors. Our TP moves to \$6.4 (old: \$7) after adjusting our DCF model for the Q2 performance.

Table 7: DCF model

In USD '000			2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Sales			90,068	120,945	161,450	198,583	234,328	269,477	299,120	329,032
NOPLAT			-10,217	-3,768	-1,666	2,822	6,950	10,528	12,534	14,675
(+) depreciation & amortisation			811	605	807	794	703	808	808	804
Net operating cash flow			-9,407	-3,163	-859	3,616	7,653	11,336	13,342	15,479
(-) Total investments (CAPEX and WC)			1,978	-1,857	-2,433	-2,482	-2,407	-2,212	-2,016	-2,118
(-) Capital expenditures			-730	-738	-985	-1,013	-961	-835	-927	-1,020
(-) Working capital			2,707	-1,120	-1,448	-1,469	-1,446	-1,377	-1,088	-1,098
Free cash flows (FCF)			-7,429	-5,020	-3,292	1,134	5,246	9,124	11,326	13,361
PV of FCF's			-7,077	-4,203	-2,422	733	2,980	4,555	4,968	5,151
						Terminal EBI	Tmargin			
In EUR '000				6.1%	6.6%	7.1%	7.6%	8.1%	8.6%	9.1%
PV of FCFs in explicit period	28,663		10.8%	8.43	9.04	9.65	10.26	10.87	11.48	12.09
(+) PV of FCFs in terminal period	37,896	ပ္	11.8%	7.22	7.71	8.20	8.68	9.17	9.66	10.14
Enterprise value (EV)	66,559	WACC	12.8%	6.26	6.65	7.05	7.44	7.83	8.23	8.62
(+) Net cash / (-) net debt	8,175	>	13.8%	5.47	5.80	6.12	6.44	6.76	7.08	7.40
(+) Investments / minority interests	0		14.8%	4.82	5.09	5.35	5.62	5.88	6.15	6.41
Shareholder value	74,735		15.8%	4.28	4.50	4.72	4.94	5.16	5.38	5.60
Fair value per share (\$)	6.40		16.8%	3.81	4.00	4.18	4.36	4.55	4.73	4.92
						Terminal gro	owth rate			
				1.0%	1.5%	2.0%	2.5%	3.0%	3.5%	4.0%
Cost of equity	15.1%		10.8%	9.23	9.54	9.88	10.26	10.68	11.17	11.73
Pre-tax cost of debt	9.0%	ပ္	11.8%	7.93	8.16	8.41	8.68	8.99	9.33	9.72
Tax rate	30.0%	WACC	12.8%	6.88	7.05	7.24	7.44	7.66	7.91	8.19
After-tax cost of debt	6.3%	3	13.8%	6.01	6.14	6.29	6.44	6.61	6.79	6.99
Share of equity capital	85.0%		14.8%	5.29	5.39	5.50	5.62	5.75	5.89	6.04
Share of debt capital	15.0%		15.8%	4.68	4.76	4.85	4.94	5.04	5.14	5.26
WACC	13.8%		16.8%	4.16	4.23	4.29	4.36	4.44	4.52	4.61

<sup>\*</sup>Please note our model runs through 2035 and we have only shown the abbreviated version for formatting purposes

## **INCOME STATEMENT**

All figures in USD '000	2020	2021	2022	2023E	2024E	2025E
Revenues	25,838	62,113	67,030	90,068	120,945	161,450
Cost of goods sold	-20,122	-47,353	-52,824	-75,753	-100,645	-133,571
Gross profit	5,716	14,760	14,206	14,315	20,301	27,879
SG&A	-6,658	-13,124	-20,971	-22,190	-21,528	-26,316
Stock-based compensation	-1,803	-1,841	-2,572	-2,342	-2,540	-3,229
Operating income (EBIT)	-2,746	-205	-12,637	-10,217	-3,768	-1,666
Net financial result	-1,498	-334	274	-192	0	0
Other non-operating result	-831	-337	-577	-1,500	0	0
Impairment loss	0	0	-2,661	0	0	0
Pre-tax income (EBT)	-5,074	-876	-15,600	-11,909	-3,768	-1,666
Income taxes	0	0	322	0	0	0
Minority interests	0	0	0	0	0	0
Net income / loss	-5,074	-876	-15,278	-11,909	-3,768	-1,666
Diluted EPS (in \$)	-1.06	-0.09	-1.44	-1.19	-0.38	-0.17
AEBITDA	-652	2,679	-3,904	-5,865	1,377	3,870
Ratios						***************************************
Gross margin	22.1%	23.8%	21.2%	15.9%	16.8%	17.3%
EBIT margin	-10.6%	-0.3%	-18.9%	-11.3%	-3.1%	-1.0%
AEBITDA margin	-2.5%	4.3%	-5.8%	-6.5%	1.1%	2.4%
Net margin	-19.6%	-1.4%	-22.8%	-13.2%	-3.1%	-1.0%
Tax rate	15.0%	21.0%	21.0%	21.0%	21.0%	21.0%
Expenses as % of revenues						
SG&A	25.8%	21.1%	31.3%	24.6%	17.8%	16.3%
Stock-based compensation	7.0%	3.0%	3.8%	2.6%	2.1%	2.0%
Y-Y Growth						
Revenues	6.8%	140.4%	7.9%	34.4%	34.3%	33.5%
Operating income	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Net income/ loss	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

## **BALANCE SHEET**

All figures in USD '000	2020	2021	2022	2023E	2024E	2025E
Assets						
Current assets, total	5,245	59,480	34,558	18,693	20,878	26,783
Cash and equivalents	185	34,591	12,008	2,536	1,508	3,209
Trade receivables	915	13,126	15,380	8,637	11,598	15,481
Inventories	537	515	320	623	827	1,098
Other ST assets	3,609	11,248	6,849	6,897	6,945	6,994
Non-current assets, total	2,915	14,675	27,508	27,479	27,664	27,894
Property, plant & equipment	129	208	1,307	1,316	1,328	1,344
Goodwill & other intangibles	991	9,568	21,023	20,933	21,054	21,215
Financial assets	1,710	4,210	2,559	2,585	2,611	2,637
Other LT assets	85	690	2,619	2,645	2,671	2,698
Total assets	8,161	74,155	62,066	46,171	48,542	54,677
Shareholders' equity & debt						
Current liabilities, total	14,546	25,005	24,256	17,794	21,253	25,680
Trade payables	654	6,067	9,960	6,226	8,272	10,978
ST debt	5,271	0	0	0	0	0
Customer deposits	4,879	13,345	2,571	3,455	4,639	6,124
Provisions	1,799	3,878	3,197	3,325	3,458	3,596
Other current liabilities	1,944	1,716	8,527	4,788	4,884	4,982
Long-term liabilities, total	1,021	983	3,078	3,212	3,351	3,496
Long-term debt	1,021	0	0	0	0	0
Deferred tax liabilities	0	441	1,033	1,085	1,139	1,196
Other non-current liabilities	0	542	2,045	2,127	2,212	2,300
Shareholders' equity	-7,406	48,167	34,732	25,165	23,938	25,501
Total consolidated equity and debt	8,161	74,155	62,066	46,171	48,542	54,677
Ratios						
Current ratio (x)	0.4	2.4	1.4	1.1	1.0	1.0
Quick ratio (x)	0.3	2.4	1.4	1.0	0.9	1.0
Equity ratio	-91%	65%	56%	55%	49%	47%
Net debt	6,197	-34,591	-8,175	-2,536	-1,508	-3,209
Net debt / EBITDA (x)	-9.5	-12.9	2.1	0.4	-1.1	-0.8
Net gearing	-84%	-72%	-24%	-10%	-6%	-13%
Return on equity (ROE)	69%	-2%	-44%	-47%	-16%	-7%
Capital employed (CE)	1,016	9,357	12,498	9,710	10,962	12,588
Return on capital employed (ROCE)	-270%	-2%	-101%	-105%	-34%	-13%



All figures in USD '000	2020	2021	2022	2023E	2024E	2025E
Net income	-5,074	-876	-15,278	-11,909	-3,768	-1,666
Depreciation and amortisation	258	495	1,483	811	605	807
Amortisation of financing instruments	558	104	0	0	0	0
Stock-based compensation	1,803	1,841	2,572	2,342	2,540	3,229
Other non-cash items	1,016	500	3,427	0	0	0
Tax result	0	0	-322	0	0	0
Net interest expense	0	0	-274	192	0	0
Operating cash flow	-1,438	2,064	-8,393	-8,565	-623	2,370
Change in w orking capital	-2,195	-3,628	-4,220	39	358	342
Tax paid	0	0	0	0	0	0
Net operating cash flow	-3,633	-1,564	-12,613	-8,526	-265	2,712
Cash flow from investing	-176	-8,337	-4,452	-755	-764	-1,011
Free cash flow (FCF)	-3,809	-9,901	-17,065	-9,281	-1,028	1,701
Equity inflow, net	0	57,747	30	0	0	0
Debt inflow, net	4,183	-5,756	0	0	0	0
Interest expenses paid	-638	0	0	-192	0	0
Stock buyback	0	-7,684	-4,362	0	0	0
Other adjustments	0	0	-1,186	1	0	0
Cash flow from financing	3,545	44,308	-5,518	-191	0	0
Net cash flows	-264	34,407	-22,583	-9,472	-1,028	1,701
Cash, start of the year	449	184	34,591	12,008	2,536	1,508
Cash, end of the year	184	34,591	12,008	2,536	1,508	3,209
EBITDA/share (in \$)	-0.14	0.27	-0.37	-0.59	0.14	0.39
Y-Y Growth						
Operating cash flow	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Free cash flow	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
AEBITDA / share	n.m.	n.m.	n.m.	n.m.	n.m.	181%



#### **Imprint / Disclaimer**

#### First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift:

First Berlin Equity Research GmbH Friedrichstr. 34 10117 Berlin Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680 Fax: +49 (0) 30-80 93 9 687 E-Mail: <u>info@firstberlin.com</u>

Amtsgericht Berlin Charlottenburg HR B 103329 B

UST-Id.: 251601797

Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV

First Berlin Equity Research GmbH

Authored by: Ellis Acklin, Senior Analyst

All publications of the last 12 months were authored by Ellis Acklin.

Company responsible for preparation: First Berlin Equity Research GmbH, Friedrichstraße 69, 10117

The production of this recommendation was completed on 17 August 2023 at 09:49

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

Copyright© 2023 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

#### **CONFLICTS OF INTEREST**

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involving a conflict of interests carry on those activities at a level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of urban-gro, Inc. the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the urban-gro, Inc. for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0.5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;



- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

First Berlin F.S.B. Investment-Beratungsgesellschaft mbH (hereafter FBIB), a company of the First Berlin Group, holds a stake of under 0.5% of the shares in the company which has been covered in this analysis. The analyst is not subject to any restrictions with regard to his recommendation and is therefore independent, so that we believe there is no conflict of interest.

With regard to the financial analyses of urban-gro, Inc. the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the urban-gro, Inc. for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).

First Berlin notes that is has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

#### PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

#### AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

#### ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

#### **ASSET RECOMMENDATION**

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category Current market capitalisation (in €)			2	
		0 - 2 billion	> 2 billion	
Strong Buy <sup>1</sup>	An expected favourable price trend of:	> 50%	> 30%	
Buy	An expected favourable price trend of:	> 25%	> 15%	
Add	An expected favourable price trend of:	0% to 25%	0% to 15%	
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%	
Sell	An expected negative price trend of:	< -15%	< -10%	

<sup>&</sup>lt;sup>1</sup> The expected price trend is in combination with sizable confidence in the quality and forecast security of management.

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of  $\in 0 - \in 2$  billion, and Category 2 companies have a market capitalisation of  $> \in 2$  billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

#### RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

#### **RECOMMENDATION & PRICE TARGET HISTORY**

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	27 June 2023	\$1.21	Buy	\$7.00
2	Today	\$1.11	Buy	\$6.40

#### **INVESTMENT HORIZON**

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

#### **UPDATES**

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

#### **SUBJECT TO CHANGE**

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding



- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: https://firstberlin.com/disclaimer-english-link/

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main

#### **EXCLUSION OF LIABILITY (DISCLAIMER)**

#### RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

#### **RELIABILITY OF ESTIMATES AND FORECASTS**

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

### INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE

#### **PURCHASE OF SECURITIES**

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

#### NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

#### NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

#### DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

#### **SEVERABILITY**

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

#### APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

#### **NOTICE OF DISCLAIMER**

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

#### **QUALIFIED INSTITUTIONAL INVESTORS**

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA and/or Canada.